{"id":"igpro20-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IgPro20 is a high-dose subcutaneous immunoglobulin (SCIg) preparation containing polyvalent human immunoglobulins that replaces deficient or dysfunctional antibodies in patients with primary immunodeficiency disorders. The high-dose formulation allows for less frequent dosing intervals while maintaining therapeutic immunoglobulin levels. It works by providing immediate passive immunity and helping to prevent recurrent infections in immunocompromised patients.","oneSentence":"IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:35.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders requiring immunoglobulin replacement therapy"}]},"trialDetails":[{"nctId":"NCT03033745","phase":"PHASE4","title":"Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2017-02-01","conditions":"Primary Immunodeficiency","enrollment":49},{"nctId":"NCT02027701","phase":"PHASE3","title":"Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-07-30","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":82},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hizentra"],"phase":"phase_3","status":"active","brandName":"IgPro20 (high dose)","genericName":"IgPro20 (high dose)","companyName":"CSL Behring","companyId":"csl-behring","modality":"Biologic","firstApprovalDate":"","aiSummary":"IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}